Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Follow-Up Questions
Who is the CEO of Sanofi SA?
Mr. Paul Hudson is the Chief Executive Officer of Sanofi SA, joining the firm since 2019.
What is the price performance of SNYNF stock?
The current price of SNYNF is $100.44, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Sanofi SA?
Sanofi SA belongs to Pharmaceuticals industry and the sector is Health Care
What is Sanofi SA market cap?
Sanofi SA's current market cap is $122.3B
Is Sanofi SA a buy, sell, or hold?
According to wall street analysts, 29 analysts have made analyst ratings for Sanofi SA, including 9 strong buy, 12 buy, 7 hold, 1 sell, and 9 strong sell
